WASHINGTON, D.C. (Tuesday, April 19, 2011) - The Biotechnology Industry Organization (BIO) announced today that Dr. Jörg Reinhardt, CEO of Bayer HealthCare, will provide the keynote address at the BIO China International Conference to be held October 12-13 in Shanghai, China. The event will bring together biotechnology and pharmaceutical leaders to explore business opportunities with life science companies in China.

All programs at the BIO World Congress on Industrial Biotechnology and Bioprocessing are open to attendance by members of the media. Complimentary media registration is available to editors and reporters with valid press credentials working full time for print, broadcast or web publications.

Despite the fact that U.S. Secretary of Agriculture Tom Vilsack believes that the regulation of genetically engineered agricultural products must be science-based, and that he has “no doubts about the safety of the products this system has approved and will continue to approve,” some state legislatures are considering bills requiring labeling for biotech-derived food. These bills defy existing science-based regulation and are wholly unnecessary.

Some of the most pressing challenges for the advent of personalized medicine relate to the reimbursement of novel diagnostics. Reimbursement policies must reflect the potential benefit that novel diagnostics can bring to patients and the healthcare system. This value proposition can be realized through reimbursement policy reforms that provide a clear and consistent pathway to obtain affirmative coverage, appropriate and timely coding, and market-based payment for diagnostic tests. BIO recommends that the following reforms be made to diagnostic reimbursement policy.

Klein is chairman of the governing board and a member of the peer review committee for the  California Institute for Regenerative Medicine. The Biotechnology Humanitarian Award is given out each year at the BIO International Convention .

Dr. Jay Siegel of  Johnson & Johnson Pharmaceutical Research & Development  and Janelle Curtis from the  Biotechnology Institute  discuss this year’s International BioGENEius Challenge.

BIO released a white paper on the growth and jobs potential of green chemicals.

The advanced biofuel industry can reduce reliance on oil and create green jobs; diverse federal programs are necessary to help producers secure financing for construction of projects. The Biotechnology Industry Organization (BIO) today joined 34 other companies and trade associations to ask leaders of the House Ways and Means Committee to include the language of H.R. 5142, the Grow a Renewable Energy Economy Now – Jumpstart Other Biofuels (GREEN JOB) Act of 2010, in the next appropriate revenue vehicle considered by the House.

The federal Renewable Fuel Standard provides the stable policy essential to attracting private investment to the development of advanced biofuels. The Biotechnology Industry Organization (BIO) today joined the Advanced BioFuel Association, the Renewable Fuel Association, the Advanced Ethanol Council and the American Coalition for Ethanol in a letter to leaders of the House Committee on Energy and Commerce and the Senate Committee on Environment and Public Works urging protection of the federal RFS.

The Biotechnology Industry Organization (BIO) today thanked Agriculture Secretary Tom Vilsack and Energy Secretary Steven Chu on the announcement of Biomass Research And Development Initiative grants and the establishment of a Biomass Crop Assistance Plan project area. BIO congratulated member companies Cellana LLC of Hawaii and Metabolix Inc. of Massachusetts on receiving awarded grants.

This paper demonstrates that the federal Renewable Fuel Standard (RFS) established under the Energy Policy Act of 2005, enhanced pursuant to the Energy Independence and Security Act of 2007 (EISA), and enforced by the Environmental Protection Agency (EPA) provides considerable market motivation to drive investment in cellulosic and advanced biofuels.

The number of Americans diagnosed with diabetes — the seventh leading cause of death in the U.S. — has risen by epidemic proportions. In addition, the disease is estimated to affect 435 million people worldwide by 2030. BIO and the Juvenile Diabetes Research Foundation will feature a two-day diabetes forum for the first time at the 2011 BIO International Convention in Washington, DC. The sessions will showcase the latest research in novel therapies, vaccines, and biomarkers.

Scientific American will release the third annual Worldview: A Global Biotechnology Perspective at this year's BIO International Convention.

This week is National Small Business Week (May 16-20). Every year, the president proclaims National Small Business Week to recognize the contributions of small businesses to the economic well-being of America. More than half of all Americans either own or work for a small business. In honor of National Small Business Week, BIO compiled our top 5 strategies for small business success.

The successful construction of a synthesized genome could enable new research and development of human therapies, biofuels, and biobased chemicals from renewable resources.

Emerging biotech companies with promising scientific innovation need a policy environment that will enable them to continue critical research and development of medical advancements and breakthroughs.

This week is National Small Business Week (May 16-20). Every year, the president of the United States proclaims National Small Business Week to recognize the contributions of small businesses to the economic well-being of America.

Providing legal counsel within the biotech industry comes with a unique set of challenges.  Legal professionals must consistently stay on top of the latest policy and regulatory changes within the industry. From patent issues to new laws on licensing to regulations for new innovations, the BIO International Convention (June 27-30) will feature the latest updates, insights and networking opportunities—plus educational sessions where you can earn up to eight CLE credit hours—to help fast-track your career. Sit in on any number of BIO Program presentations by leading law firms and earn CLE credits.

You might have heard that the Prince of Wales, just days after hosting the Royal Wedding, paid us a visit here in Washington.  Prince Charles, a long-time organic food advocate and self-described environmentalist, was here to speak at a Washington Post symposium on the Future of Food.

Prince Charles likes to talk about “sustainability” so much that he used a version of the word 32 times in his recent speech about farming at Georgetown University.

Recently introduced legislation could help the military become the technology leader in scaling up commercial production of sustainable biofuels, such as algae.

Multiple sclerosis (MS) is a complex disease involving immune-system attacks on the central nervous system. Research into MS involves questions that dovetail many fields of science, including immunology, neuroscience, psychology and more.

The world’s largest biotech hubs are busy planning their delegations’ visits to the  BIO International Convention  next month. The international program at the Convention will be one of the most robust to date, with International Case Studies, breakout sessions focused on globalization and Super Sessions focused on the emerging markets.

The keys to successful industrial biotech business relationships mirror those for successful personal relationships, industry leaders explained today.  During the final Lunch Plenary Session of BIO’s 2011 World Congress in Toronto, moderator James Stoppert, CEO of BioAdvisors, along with panelists Patrick Gruber, CEO of Gevo, Ron Commander, Head of Butyl Rubber Business Unit at Lanxess, Christophe Schilling, CEO of Genomatica, and Hisao Urata, General Manager of Corporate Planning at Mitsubishi Chemical discussed “Strategic Partnerships for More Robust Value Chains” and identified some key components to that end.